Intracolonic Vancomycin Therapy in Severe C. Diff Colitis

This study has been terminated.
Sponsor:
Information provided by (Responsible Party):
Marc Grodsky, William Beaumont Hospitals
ClinicalTrials.gov Identifier:
NCT01346059
First received: March 3, 2011
Last updated: September 15, 2012
Last verified: April 2011
  Purpose

Clostridium difficile is a bacteria that can infect the colon and cause severe diarrhea in patients after recent antibiotic use. The current standard of care treatment for severe C. diff. consists of oral vancomycin and/or intravenous metronidazole. When treatment is unsuccessful, it can lead to need for removal of the entire colon or even death. In fact, mortality rates in the literature range from 11-37% for C. diff. The most commonly quoted mortality rate is 14% for severe infection. It is believed that the failure of treatment may stem from an adynamic ileus (paralysis of the small bowel). This ileus may prevent the oral vancomycin from reaching the colon and therefore it does not treat the problem. Vancomycin functions by direct contact with the colon. Therefore, if the vancomycin is instilled directly into the colon, it can come into contact with and be its intended target. : The objective of the study is to improve treatment of severe C. diff. colitis . C. diff. infection is defined as severe if there is evidence of ileus accompanied by any one of the following: fever greater than 38.30C, , acidemia, serum albumin less than 2.5, or white blood cell count greater than 14,000.


Condition Intervention
Colitis
Drug: Vancomycin
Drug: Saline

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver)
Primary Purpose: Treatment
Official Title: Intracolonic Vancomycin Therapy in Severe C. Diff Colitis: A Double Blinded Randomized Prospective Trial

Resource links provided by NLM:


Further study details as provided by William Beaumont Hospitals:

Primary Outcome Measures:
  • Resolution of diarrhea and white blood cell count elevation [ Time Frame: 14 days ] [ Designated as safety issue: Yes ]
    If the patient has resolution of diarrhea, white blood cell count, and abdominal pain, the protocol will be stopped.


Secondary Outcome Measures:
  • Mortality [ Time Frame: 30 day ] [ Designated as safety issue: No ]
  • Need for colectomy [ Time Frame: 30 day ] [ Designated as safety issue: No ]

Enrollment: 2
Study Start Date: April 2011
Study Completion Date: February 2012
Primary Completion Date: February 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Saline
The saline arm will receive normal saline through the catheter as a placebo.
Drug: Saline
Saline, used as a placebo, will be instilled through the colonic catheter. Every 6 hours, 250cc of saline will be used.
Other Name: Normal Saline
Experimental: Vancomycin
The vancomycin arm will receive vancomycin solution through the catheter.
Drug: Vancomycin
Vancomycin solution will be instilled through the colonic catheter every 6 hours. 250cc of solution will be used each time. The solution is 2 grams vancomycin mixed in 1 liter normal saline.
Other Name: Vancocin

Detailed Description:

Patients in the surgical intensive care unit with severe C. diff. are eligible and if consented will be randomized in a 1:1 ratio to a control group or the treatment group. Each group will undergo a colonoscopy on day one of the study. A 14 French Cook colonic decompression catheter will be placed at that time. This catheter is a 175cm long soft flexible catheter designed to be placed in the colon. Its usual use is to remove air from a colon that is dilated. The catheter is placed into the colon by first placing a guidewire through the colonoscope. The colonoscope is then removed leaving the guidewire in place. The catheter is then thread into the colon over the guidewire. An xray is obtained to confirm the location of the catheter and then the guidewire is removed. The guidewire is a very thin, soft, flexible wire. The patient will not have any undue discomfort secondary to the catheter. The control group will have 250cc of sterile saline solution instilled through the catheter into the colon every 6 hours. The study group will have 250cc of vancomycin solution instilled every 6 hours. The solution will be 2 grams vancomycin dissolved in a 1 liter normal saline irrigation bottle. The catheter will be clamped in both groups after instillation until the next treatment. Of note, both groups will receive the current standard treatment of 500mg IV metronidazole every 8 hours and 250mg oral vancomycin every 6 hours throughout the study. Every day the patients will have a blood draw to check the white blood cell count as is the current practice. The patients will also have a vancomycin trough level checked via blood test. This will occur just prior to the first dosing on treatment day number 3. This will be a blinded lab value as to not unblind the investigators. At resolution Patients will undergo a repeat colonoscopy when there is a decrease of diarrhea (less than 3 stools daily) and a normalized white blood cell count or on day 7 if symptoms persist. The expected length of treatment is approximately 7 days. If there is no improvement at fourteen days, the trial will be stopped for futility. The trial will also be halted if the attending physician determines that the patient needs surgery or if the clinical status of the patient has deteriorated to a point where keeping the patient enrolled will potentially cause harm. Follow-up after completing the trial will consist of phone interviews to screen for recurrence of infection. A weekly phone call will be made for the first three weeks and then two monthly calls will take place after that for a total of three months follow-up. The primary investigator will make these phone calls.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • SICU patient
  • positive c. diff toxin assay
  • visualization of pseudomembranes on colonoscopy,
  • able to give consent or have representative to give consent.

Exclusion Criteria:

  • Under age 18
  • pregnant
  • absence of a colon or surgical discontinuity of bowel
  • allergy to vancomycin
  • need for anti-diarrheal medication
  • need for prolonged antibiotics for other cause
  • need for probiotics
  • need for other medications with action against C. diff.
  • need for surgery, colon perforation
  • recent IV IG use
  • toxic megacolon.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01346059

Locations
United States, Michigan
William Beaumont Hospital
Royal Oak, Michigan, United States, 48073
Sponsors and Collaborators
Marc Grodsky
Investigators
Principal Investigator: Marc B Grodsky, MD William Beaumont Hospitals
  More Information

No publications provided

Responsible Party: Marc Grodsky, Principal Investigator, William Beaumont Hospitals
ClinicalTrials.gov Identifier: NCT01346059     History of Changes
Other Study ID Numbers: 2010-195
Study First Received: March 3, 2011
Last Updated: September 15, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by William Beaumont Hospitals:
Clostridium
Colitis
Intracolonic vancomycin
psuedomembranous colitis

Additional relevant MeSH terms:
Colitis
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Colonic Diseases
Intestinal Diseases
Vancomycin
Anti-Bacterial Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on September 14, 2014